LivaNova

LivaNova PLC is a global medical technology company based in London, UK. Established in 2015 through a merger between Cyberonics, Inc. and Sorin S.p.A., LivaNova specializes in innovative medical devices and therapies for neurological and cardiac conditions. The company operates in two main segments: Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides a variety of products, including heart-lung machines and oxygenators, used in cardiac surgery. The Neuromodulation segment focuses on the Vagus Nerve Stimulation (VNS) Therapy System, which treats difficult-to-treat depression and drug-resistant epilepsy. LivaNova serves a diverse customer base, including healthcare providers and medical institutions, distributing its products in over 100 countries. With around 2,900 employees, LivaNova reported revenues of approximately $1.25 billion in 2024. The company is committed to high quality and ethical practices, aiming to improve patient outcomes through its advanced therapies for heart and brain conditions.